Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2021 | Post-transplant relapse in Ph+ ALL

Ali Bazarbachi • 12 Mar 2021
EBMT 2021
Antibodies Blinatumomab CAR-T Inotuzumab ozogamicin

Allogeneic transplantation represents a cure for many patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Ali Bazarbachi, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon, highlights some of the treatment options for those who relapse post-transplant. Specifically mentioned is the withdrawal of immunosuppression, chemotherapy, Tyrosine kinase inhibitors (TKIs), donor lymphocyte infusion and second allogeneic transplantation. Prof. Bazarbachi goes on to highlight how monoclonal antibody and CAR-T therapies continue to improve outcomes. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

More from Ali Bazarbachi

6:52
Somatic mutations that impact alloSCT outcomes in patients with AML
Ali Bazarbachi • 19 Dec 2023
8:11
Improvements over time in elderly patients with AML treated with alloSCT: an EBMT Registry study
Ali Bazarbachi • 19 Dec 2023
11:16
Latest advancements in alloHSCT for ALL
Ali Bazarbachi • 21 Mar 2022
9:06
Advances in the management of R/R Hodgkin lymphoma
Ali Bazarbachi • 28 Sep 2021
The content of VJHemOnc is intended for healthcare professionals